Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
A dose-escalation study Appetite
Sous forme injectable, il peut tre utilis en milieu hospitalier
Molecular targets for ADCs in prostate cancer The successful development of radioligand therapies for prostate cancer, such as lutetium vipivotide tetraxetan (177Lu-PSMA-617), as well as advances in the understanding of histological features and expression of prostate cancer antigens reinvigorated the landscape of ADC development in prostate cancer 66
After that, the interest appeared to cease
US$ 23.13
US$ 29.63
US$ 26.11
US$ 29.65
US$ 20.32
US$ 29.91
US$ 25.93
US$ 22.89
